Identification of potential inhibitors of Schistosoma mansoni purine nucleoside phosphorylase from neolignan compounds using molecular modelling approaches. 2022

Fábio José Bonfim Cardoso, and Luciana Pereira Xavier, and Agenor Valadares Santos, and Humberto D'Muniz Pereira, and Lourivaldo da Silva Santos, and Fábio Alberto de Molfetta
Laboratório de Modelagem Molecular, Instituto de Ciências Exatas e Naturais, Universidade Federal do Pará, Belém, Pará, Brazil.

Schistosomiasis is a parasitic disease that is part of the neglected tropical diseases (NTDs), which cause significant levels of morbidity and mortality in millions of people throughout the world. The enzyme purine nucleoside phosphorylase from Schistosoma mansoni (SmPNP) represents a potential target for discovering new agents, and neolignans stand out as an important class of compounds. In this work, molecular modeling studies and biological assays of a set of neolignans were conducted against the PNP enzymes of the parasite and the human homologue (HssPNP). The results of the molecular docking described that the neolignans showed good complementarity by the active site of SmPNP. Molecular dynamics (MD) studies revealed that both complexes (Sm/HssPNP - neolignan compounds) were stable by analyzing the root mean square deviation (RMSD) values, and the binding free energy values suggest that the selected structures can interact and inhibit the catalytic activity of the SmPNP. Finally, the biological assay indicated that the selected neolignans presented a better molecular profile of inhibition compared to the human enzyme, as these ligands did not have the capacity to inhibit enzymatic activity, indicating that these compounds are promising candidates and that they can be used in future research in chemotherapy for schistosomiasis.Communicated by Ramaswamy H. Sarma.

UI MeSH Term Description Entries
D011683 Purine-Nucleoside Phosphorylase An enzyme that catalyzes the reaction between a purine nucleoside and orthophosphate to form a free purine plus ribose-5-phosphate. EC 2.4.2.1. Inosine Phosphorylase,Nicotinamide Riboside Phosphorylase,Purine Nucleoside Phosphorylases,Nucleoside Phosphorylases, Purine,Phosphorylase, Inosine,Phosphorylase, Nicotinamide Riboside,Phosphorylase, Purine-Nucleoside,Phosphorylases, Purine Nucleoside,Purine Nucleoside Phosphorylase,Riboside Phosphorylase, Nicotinamide
D004791 Enzyme Inhibitors Compounds or agents that combine with an enzyme in such a manner as to prevent the normal substrate-enzyme combination and the catalytic reaction. Enzyme Inhibitor,Inhibitor, Enzyme,Inhibitors, Enzyme
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D012550 Schistosoma mansoni A species of trematode blood flukes of the family Schistosomatidae. It is common in the Nile delta. The intermediate host is the planorbid snail. This parasite causes schistosomiasis mansoni and intestinal bilharziasis. Schistosoma mansonus,mansonus, Schistosoma
D012552 Schistosomiasis Infection with flukes (trematodes) of the genus SCHISTOSOMA. Three species produce the most frequent clinical diseases: SCHISTOSOMA HAEMATOBIUM (endemic in Africa and the Middle East), SCHISTOSOMA MANSONI (in Egypt, northern and southern Africa, some West Indies islands, northern 2/3 of South America), and SCHISTOSOMA JAPONICUM (in Japan, China, the Philippines, Celebes, Thailand, Laos). S. mansoni is often seen in Puerto Ricans living in the United States. Bilharziasis,Katayama Fever,Schistoma Infection,Bilharziases,Fever, Katayama,Infection, Schistoma,Infections, Schistoma,Schistoma Infections,Schistosomiases
D017705 Lignans A class of dibenzylbutane derivatives which occurs in higher plants and in fluids (bile, serum, urine, etc.) in man and other animals. These compounds, which have a potential anti-cancer role, can be synthesized in vitro by human fecal flora. (From Singleton & Sainsbury, Dictionary of Microbiology and Molecular Biology, 2d ed) Lignan,Neolignan,Neolignans
D062105 Molecular Docking Simulation A computer simulation technique that is used to model the interaction between two molecules. Typically the docking simulation measures the interactions of a small molecule or ligand with a part of a larger molecule such as a protein. Molecular Docking,Molecular Docking Simulations,Molecular Docking Analysis,Analysis, Molecular Docking,Docking Analysis, Molecular,Docking Simulation, Molecular,Docking, Molecular,Molecular Docking Analyses,Molecular Dockings,Simulation, Molecular Docking

Related Publications

Fábio José Bonfim Cardoso, and Luciana Pereira Xavier, and Agenor Valadares Santos, and Humberto D'Muniz Pereira, and Lourivaldo da Silva Santos, and Fábio Alberto de Molfetta
May 2013, Analytical and bioanalytical chemistry,
Fábio José Bonfim Cardoso, and Luciana Pereira Xavier, and Agenor Valadares Santos, and Humberto D'Muniz Pereira, and Lourivaldo da Silva Santos, and Fábio Alberto de Molfetta
January 2011, Journal of synchrotron radiation,
Fábio José Bonfim Cardoso, and Luciana Pereira Xavier, and Agenor Valadares Santos, and Humberto D'Muniz Pereira, and Lourivaldo da Silva Santos, and Fábio Alberto de Molfetta
October 2005, Journal of molecular biology,
Fábio José Bonfim Cardoso, and Luciana Pereira Xavier, and Agenor Valadares Santos, and Humberto D'Muniz Pereira, and Lourivaldo da Silva Santos, and Fábio Alberto de Molfetta
June 2003, Acta crystallographica. Section D, Biological crystallography,
Fábio José Bonfim Cardoso, and Luciana Pereira Xavier, and Agenor Valadares Santos, and Humberto D'Muniz Pereira, and Lourivaldo da Silva Santos, and Fábio Alberto de Molfetta
October 2021, The Biochemical journal,
Fábio José Bonfim Cardoso, and Luciana Pereira Xavier, and Agenor Valadares Santos, and Humberto D'Muniz Pereira, and Lourivaldo da Silva Santos, and Fábio Alberto de Molfetta
February 2010, Bioorganic & medicinal chemistry,
Fábio José Bonfim Cardoso, and Luciana Pereira Xavier, and Agenor Valadares Santos, and Humberto D'Muniz Pereira, and Lourivaldo da Silva Santos, and Fábio Alberto de Molfetta
January 2011, Biomeditsinskaia khimiia,
Fábio José Bonfim Cardoso, and Luciana Pereira Xavier, and Agenor Valadares Santos, and Humberto D'Muniz Pereira, and Lourivaldo da Silva Santos, and Fábio Alberto de Molfetta
November 1986, Federation proceedings,
Fábio José Bonfim Cardoso, and Luciana Pereira Xavier, and Agenor Valadares Santos, and Humberto D'Muniz Pereira, and Lourivaldo da Silva Santos, and Fábio Alberto de Molfetta
February 1990, The Journal of biological chemistry,
Fábio José Bonfim Cardoso, and Luciana Pereira Xavier, and Agenor Valadares Santos, and Humberto D'Muniz Pereira, and Lourivaldo da Silva Santos, and Fábio Alberto de Molfetta
January 2018, Current topics in medicinal chemistry,
Copied contents to your clipboard!